查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1888591

全球肺动脉高血压市场：市场规模、份额、趋势分析（按药物类别、类型、给药途径和地区划分）、细分市场预测（2025-2033 年）

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肺动脉高血压市场概览

2024年全球肺动脉高血压市场规模估计为80.2亿美元，预计2033年将达到133.4亿美元。

预计从 2025 年到 2033 年，该市场将以 5.9% 的复合年增长率成长。推动市场成长的关键因素包括政府和医疗机构对新药研发的支持力度加大、肺动脉高血压盛行率上升以及有利的报销政策。

此外，肺动脉高血压领域的大规模研究和开发预计也将对市场成长产生积极影响。例如，2023年12月，西达赛奈医疗中心的一组研究人员发现，一种独特的细胞疗法适用于治疗肺动脉高血压。该研究目前正处于I期临床试验阶段。

肺动脉高压（PAH）市场受益于产业领导企业和各国政府的大量投资，旨在满足这种罕见疾病尚未满足的医疗需求。推动市场成长的因素包括：与吸烟、爱滋病等生活方式因素相关的PAH发病率不断上升，以及人口老化。美国《孤儿药法案》等政府政策正在促进药物研发并支持市场扩张。诊断能力的提升和公众意识的增强也进一步推动了对有效治疗方法的需求。

前列腺环素及其类似物仍将占据重要地位，预计到2024年将占总收入的47.11%。依前列醇和Selexipag等药物具有血管扩张作用。它们能够改善肺血流和患者生活质量，从而巩固主导地位。口服製剂等创新疗法提高了药物的可及性，并透过改善患者依从性推动了该领域的成长。

索他塞普（商品名：Winlever）于2024年3月获得美国食品药物管理局（FDA）核准，用于治疗成人肺动脉高血压（PAH）患者。它是首个核准用于治疗PAH的激活素讯号通路抑制剂，已被证实能够提高运动耐量、改善WHO功能分级并降低临床恶化事件的风险。

新兴技术，例如2021年推出的Remunity泵，正在革新药物输送方式，实现曲前列尼尔的皮下注射。包括穿戴式装置在内的数位健康工具，能够实现即时监测，并促进个人化的肺动脉高压管理。这些进步，加上强大的研发开发平臺，可望重塑治疗模式，并维持市场成长至2033年。

目录

第一章 分析方法和范围

第二章执行摘要

第三章肺动脉高血压市场：影响因素、趋势与范围

  • 市场联动展望
  • 市场动态
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章肺动脉高血压市场：按药物类别分類的业务分析

  • 按药物类别分類的市场份额（2024 年和 2033 年）
  • 肺动脉高血压市场：按药物类别分類的趋势分析（2023 年和 2030 年）
  • 内皮素受体拮抗剂（ERA）
  • PDE-5抑制剂
  • 前列腺环素和前列腺环素类似物
  • SGC 兴奋剂

第五章肺动脉高血压市场：按类型分類的业务分析

  • 按类型分類的市场份额（2024 年和 2033 年）
  • 肺动脉高血压市场：按类型分類的趋势分析（2023 年和 2030 年）
  • 品牌药
  • 学名药

第六章肺动脉高血压市场：依给药途径分類的业务分析

  • 按给药途径分類的市场份额（2024 年和 2033 年）
  • 肺动脉高血压市场：按给药途径分類的变化分析（2023 年和 2030 年）
  • 口服
  • 静脉注射/皮下注射
  • 吸入

第七章：区域商业分析

  • 肺动脉高血压市场份额（按地区划分，2023 年和 2030 年）
  • 北美洲
    • 北美肺动脉高血压市场（2021-2033 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲肺动脉高血压市场（2021-2033）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 亚太地区肺动脉高血压市场（2021-2033）
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲肺动脉高血压市场（2021-2033 年）
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家
  • 中东和非洲
    • 中东和非洲肺动脉高血压市场（2021-2033 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 公司分类
  • 策略规划
  • 企业市场占有率分析（2023）
  • 公司简介/列表
    • United Therapeutics Corporation
    • Johnson &Johnson Services Inc.
    • Bayer AG
    • Gilead Sciences, Inc.
    • Viatris Inc.
    • GlaxoSmithKline
    • Novartis AG
    • Lupin Pharmaceuticals Inc.
    • Sun Pharmaceutical Industries, Inc.
    • Teva Pharmaceuticals Industries Ltd.
Product Code: GVR-2-68038-855-8

Pulmonary Arterial Hypertension Market Summary

The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market growth is majorly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies.

In addition, substantial research and development activities in the field of pulmonary arterial hypertension are also projected to have a positive impact on the market's growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.

The PAH market thrives on significant investments from industry leaders and governments, targeting the unmet needs of this rare condition. Growth is driven by increasing PAH incidence linked to lifestyle factors such as smoking and HIV, alongside aging populations. Government policies, such as the U.S. Orphan Drug Act, incentivize drug development, boosting market expansion. Enhanced diagnostic capabilities and awareness further accelerate demand for effective therapies.

Prostacyclin and analogs, holding 47.11% of 2024 revenue, remain pivotal, with drugs such as epoprostenol and selexipag offers vasodilation benefits. Their ability to improve pulmonary blood flow and patient quality of life underpins their market leadership. Innovations like oral formulations enhance accessibility, and drive segment growth through improved patient adherence.

Sotatercept (Winrevair) has been FDA approved in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH). It is the first activin signaling inhibitor approved for PAH, shown to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.

Emerging technologies, such as the Remunity Pump launched in 2021, revolutionize drug delivery, offering subcutaneous treprostinil administration. Digital health tools, including wearables, enable real-time monitoring, personalizing PAH management. These advancements, paired with a strong R&D pipeline, promise to reshape treatment paradigms and sustain market momentum through 2033.

Global Pulmonary Arterial Hypertension Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Endothelin Receptor Antagonists (ERAs)
  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generics
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Intravenous/ subcutaneous
  • Inhalational
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
    • Rest of LA
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. By Type
    • 1.2.3. Route of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
    • 1.9.1. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pulmonary Arterial Hypertension Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Pulmonary Arterial Hypertension Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
  • 4.4. Endothelin Receptor Antagonists (ERAs)
    • 4.4.1. Endothelin Receptor Antagonists (ERAs) Market, 2021 - 2033 (USD Million)
  • 4.5. PDE-5 Inhibitors
    • 4.5.1. PDE-5 Inhibitors Market, 2021 - 2033 (USD Million)
  • 4.6. Prostacyclin and Prostacyclin Analogs
    • 4.6.1. Prostacyclin and Prostacyclin Analogs Market, 2021 - 2033 (USD Million)
  • 4.7. SGC Stimulators
    • 4.7.1. SGC Stimulators Market, 2021 - 2033 (USD Million)

Chapter 5. Pulmonary Arterial Hypertension Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Branded
    • 5.3.1. Branded Market, 2021 - 2033 (USD Million)
  • 5.4. Generic
    • 5.4.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 6. Pulmonary Arterial Hypertension Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2033
  • 6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Oral
    • 6.3.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.4. Intravenous/ Subcutaneous
    • 6.4.1. Intravenous/ Subcutaneous Market, 2021 - 2033 (USD Million)
  • 6.5. Inhalational
    • 6.5.1. Inhalational Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Mexico Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. France Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.3.9. Denmark
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. India Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. ArgentinaPulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.5.4. Rest of LATAM
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Rest of LATAM Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. United Therapeutics Corporation
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Bayer AG
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Gilead Sciences, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Viatris Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. GlaxoSmithKline
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Novartis AG
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Lupin Pharmaceuticals Inc.
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Sun Pharmaceutical Industries, Inc.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Teva Pharmaceuticals Industries Ltd.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Average selling prices for approved PAH agents in the U.S. (2023)
  • Table 3 Summary of pipeline analysis for Early Phase I & Phase I PAH agents
  • Table 4 Summary of pipeline analysis for Phase II PAH agents
  • Table 5 Summary of pipeline analysis for Phase III PAH agents
  • Table 6 Summary of pipeline analysis for Phase IV PAH agents
  • Table 7 Summary of pipeline analysis for Phase IV PAH agents
  • Table 8 Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2021 - 2033 ( USD Million)
  • Table 9 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 10 Global Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 11 Global Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 12 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 13 North America Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
  • Table 14 North America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 15 North America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 16 North America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 17 U.S. Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 18 U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 19 U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 20 Canada Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 22 Canada Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 23 Europe Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
  • Table 24 Europe Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 25 Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 26 Europe Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 27 UK Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 28 UK Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 29 UK Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 30 Germany Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 31 Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 32 Germany Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 33 France Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 34 France Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 35 France Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 36 Italy Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 37 Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 38 Italy Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 39 Spain Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 40 Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 41 Spain Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 42 Sweden Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 44 Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 45 Denmark Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 47 Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 48 Norway Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 49 Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 50 Norway Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 54 Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 55 China Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 56 China Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 57 China Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 58 Japan Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 60 Japan Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 61 India Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 62 India Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 63 India Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 64 Australia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 65 Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 66 Australia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 67 South Korea Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 69 South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 70 Thailand Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 71 Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 72 Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 73 Latin America Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
  • Table 74 Latin America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 75 Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 76 Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 77 Brazil Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 78 Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 79 Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 80 Mexico Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 81 Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 82 Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 83 Argentina Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 84 Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 85 Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 86 MEA Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
  • Table 87 MEA Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 88 MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 89 MEA Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 90 South Africa Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 91 South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 92 South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 93 Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 94 Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 95 Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 96 UAE Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 97 UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 98 UAE Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
  • Table 99 Kuwait Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
  • Table 100 Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 101 Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pulmonary Arterial Hypertension market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Pulmonary Arterial Hypertension market dynamics
  • Fig. 12 Pulmonary Arterial Hypertension market Porter's five forces analysis
  • Fig. 13 Pulmonary Arterial Hypertension market PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 15 Endothelin Receptor Antagonists (ERAs) market, 2021 - 2033 (USD Million)
  • Fig. 16 PDE-5 Inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 17 Prostacyclin and Prostacyclin Analogs market, 2021 - 2033 (USD Million)
  • Fig. 18 SGC Stimulators market, 2021 - 2033 (USD Million)
  • Fig. 19 Type market, 2021 - 2033 (USD Million)
  • Fig. 20 Branded market, 2021 - 2033 (USD Million)
  • Fig. 21 Generics market, 2021 - 2033 (USD Million)
  • Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
  • Fig. 23 Oral market, 2021 - 2033 (USD Million)
  • Fig. 24 Intravenous/ Subcutaneous market, 2021 - 2033 (USD Million)
  • Fig. 25 Inhalational market, 2021 - 2033 (USD Million)
  • Fig. 26 Pulmonary Arterial Hypertension market revenue, by region
  • Fig. 27 Regional marketplace Key takeaways
  • Fig. 28 North America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework